InvestorsHub Logo
Followers 74
Posts 3281
Boards Moderated 0
Alias Born 03/16/2014

Re: None

Thursday, 12/17/2020 6:30:48 AM

Thursday, December 17, 2020 6:30:48 AM

Post# of 716278
Merck, Eisai Say Keytruda Study Met Primary, Secondary Endpoints in Patients With Advanced Endometrial Cancer
(MT Newswires)
Merck & Co. (MRK), in partnership with Eisai, said Wednesday its phase 3 study of Keytruda in combination with Lenvima met the primary and secondary efficacy endpoints in patients with advanced endometrial cancer.

Based on the results, the combination therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival, progression-free survival and overall response rate. The safety profile of the combination therapy was also consistent with previously reported studies.

Merck and Eisai intend to submit marketing authorization applications based on these results, according to a statement. Price: 80.99, Change: +0.51, Percent 
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News